Analysts Project Four Major Pharma Companies Most Hit by US Drug Pricing Reform

As the US Senate moves closer to passing a bill that would allow Medicare to negotiate drug prices, analysts are busy projecting the impact to the pharma industry. According to analysts from SVB Securities, Eli Lilly, Abbvie, Johnson & Johnson, and Astrazeneca will be especially impacted if the proposal passes.

According to the analysts, “We are concerned about the negative impact of proposed legislation on future innovation and the financials associated with some of the most helpful drugs for Medicare recipients. Not only would the economics for many drugs be curtailed before loss of exclusivity, but innovators’ willingness to develop new drugs, in particular small molecule therapies for seniors, would likely diminish.”

To read more, click here.

(Source: Fierce Pharma, August 1st, 2022)